1. During the early on 2000s US-Israel pharma gaint Teva Pharmaceutical Industries Ltd marketed Copaxone® (a xx milligram daily injection) for the handling of multiple sclerosis, a illness inward which the insulating covers of nervus cells inward the encephalon as well as spinal cord are damaged. The active factor of Copaxone® is glatiramer acetate known every bit copolymer-1.
To know much much coin Copaxone makes, nosotros should await at the sales figure as well as toll of this drug. Annual sales of Copaxone® are exactly about US$4.3 billon worldwide as well as draw of piece of job organisation human relationship for to a greater extent than than one-half of Teva’s profit. Copaxone® is rattling expensive alongside many patients paying over US$40,000 (Rs. 26,00,000) per yr for the drug. The production is protected past times nearly 10 patents issued betwixt 1998 as well as 2013.
2. In 2003, Natco Pharma Limited (Natco) began inquiry to prepare a generic version of Copaxone® inward social club to brand a cost effective version of the drug available to patients inward India. As a final result of its efforts, Natco developed a new procedure for producing copolymer-1 as well as filed patent applications roofing its process. Presently, Natco’s copolymer-1 production is sold inward Republic of Republic of India nether the grade “GLATIMER”.
 |
| Natco Pharma |
3. Ashish Chugh entered Natco Pharma at Rs. 70. I believe to a higher house tidings indicate was the trigger indicate for Ashish's conclusion to larn inward the stock.
4. In 2003, Yeda, the inquiry fly of Teva filed application for the production glatiramer acetate inward India. Influenza A virus subtype H5N1 pre-grant opposition was filed past times Natco raising issues of inventive footstep as well as an objection nether Section 3(d) of the Indian Patents Act, 1970. Influenza A virus subtype H5N1 bad tidings of for an investor to trigger the piece of job out call. But Ashish Chugh kept calm as well as stayed invested.
5. In 2008, Mylan Pharmaceuticals Inc. (Mylan) signed a license as well as provide understanding alongside Natco for generic copolymer-1 pre-filled syringes. The understanding granted Mylan exclusive distribution rights inward the U.S. as well as all major markets inward Europe, Australia, New Zealand, Nippon as well as Canada as well as included an pick to expand into additional territories.
Stock reacted positively as well as it reached Rs.159, which doubled the coin of Ashish Chugh. This every bit a peachy tidings for an investor who held the stock for v years to piece of job out as well as await for other options. But Ashish Chugh kept calm as well as stayed invested.
 |
| Ashish Chugh |
6. Recession on amount swing. Natco Pharma was non an exception. By the destination of 2008, Natco Pharma savage downwards to nearly Rs. 65, which is around 10 per centum below Ashish's entry toll of Rs.70 inward 2003. What would bring been the reaction of a normal investor?. You stayed invested inward a stock a stock for around six years as well as destination upward alongside a negative return!!. Influenza A virus subtype H5N1 classic illustration to piece of job out as well as motion on. But Ashish Chugh kept calm as well as stayed invested.
7. The application submitted past times Yeda inward 2003 for the production glatiramer acetate inward Republic of Republic of India endure rejected inward March, 2009. In spite of that, Yeda obtained Indian Patent Number 190759 claiming a procedure for manufacturing of generic drug.
8. In 2012, Teva filed a 2d trial against Natco inward the High Court seeking a permanent injunction to limit Natco as well as its agents from straight or indirectly manufacturing, selling, offering for sale, exporting or registering the production that had been held past times the U.S. District Court from infringing its patent. Similar to the get-go lawsuit, Teva sought an accounting of Natco’s profits as well as a decree for damages.
By this fourth dimension Natco Pharma was trading at Rs. 350. It was a expert fourth dimension for Ashish Chugh to piece of job out the stock every bit it was became a v bagger for him. But Ashish Chugh kept calm as well as stayed invested.
9. In February, 2014, the High Court of Delhi dismissed Teva’s trial seeking an injunction to preclude Natco from exporting its generic version of Copaxone®. The High Court reviewed the 2 processes used past times Natco to industry copolymer-1 as well as noted that the acquaint conform involved the procedure used past times Natco for manufacturing copolymer-1 inward Republic of Republic of India on behalf of Mylan for sale exterior of Republic of Republic of India as well as non the procedure used past times Natco for manufacturing copolymer-1 inward Republic of Republic of India for sale inside India.
That every bit much awaited tidings for an investor to piece of job out as well as realize a 10 bagger past times that time. Stock toll was inward Rs.700s. But Ashish Chugh kept calm as well as stayed invested.
10. As of today, the stock is trading at Rs. 780 later split. We are certain Ashish Chugh is waiting patiently for the stock to achieve Rs. 2500 range, which volition larn his get-go 100 bagger stock.
 |
| The mental attitude y'all bespeak during turbulent times!! |
Sometimes, y'all brand coin past times non buying or selling stocks, but past times only staying invested!!!. Keep calm as well as rest invested!!!